Please login to the form below
PharmaMar
This page shows the latest PharmaMar news and features for those working in and with pharma, biotech and healthcare.
PharmaMar’s cancer drug has ‘potent preclinical efficacy’ against COVID-19
However, PharmaMar added that while the toxicity is a ‘concern’, the doses used in its COVID-19 clinical trials are well tolerated in humans. ... PharmaMar added in a statement that it is discussing the launch of phase 3 trials with different
Latest news
-
Jazz Pharma’s SCLC drug fails to meet primary endpoint in combo trial
Drug combination failed to improve overall survival rate. Jazz Pharmaceuticals and PharmaMar have revealed that their small cell lung cancer (SCLC) therapy lurbinectedin has failed to meet the primary endpoint in ... Jazz licensed lurbinectedin from
-
NICE recommends two drugs for ovarian cancer but rejects three
But the cost-effectiveness body rejected GlaxoSmithKline's Hycamtin (topotecan), PharmaMar's Yondelis (trabectedin) and Lilly's Gemzar (gemcitabine) for treating the first recurrence of platinum-sensitive ovarian cancer.
-
FDA approves Janssen’s Yondelis
Luis Mora, managing director of Janssen's licensing partner PharmaMar, said: “Since Yondelis was first approved in Europe in 2007 approximately 50, 000 patients in 80 countries have benefited from this
-
PharmaMar/J&J’s Yondelis fast-tracked by FDA for sarcoma
Cancer drug could be approved in the US within months. PharmaMar's cancer drug Yondelis could be approved in the US within a few months after it was fast-tracked by ... would be "financially transformative" for PharmaMar's parent company Zeltia.
-
NICE rejection of three ovarian cancer drugs stands
NICE has over the past three years rejected three medicines for the disease: Lilly's Gemzar (gemcitabine), GlaxoSmithKline's Hycamtin (topotecan), both of which are also available as generics, and
More from news
Approximately 3 fully matching, plus 10 partially matching documents found.
Latest appointments
-
Bedrock hires new client services director
Patricia has combined her scientific and commercial understanding to work strategically with both large and small clients, including most recently Novartis, Abbott, Astellas, Bristol-Myers Squibb, PharmaMar and Roche, and we
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
PMHub
Sciterion
Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
